CN1144486A - 卵巢雌激素依赖性病症的治疗 - Google Patents

卵巢雌激素依赖性病症的治疗 Download PDF

Info

Publication number
CN1144486A
CN1144486A CN95192252A CN95192252A CN1144486A CN 1144486 A CN1144486 A CN 1144486A CN 95192252 A CN95192252 A CN 95192252A CN 95192252 A CN95192252 A CN 95192252A CN 1144486 A CN1144486 A CN 1144486A
Authority
CN
China
Prior art keywords
treatment
estrogen
antiprogestin
analog
gnrh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN95192252A
Other languages
English (en)
Chinese (zh)
Inventor
G·D·霍登
R·F·威廉斯
D·格劳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eastern Virginia Medical School
Original Assignee
Eastern Virginia Medical School
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eastern Virginia Medical School filed Critical Eastern Virginia Medical School
Publication of CN1144486A publication Critical patent/CN1144486A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
CN95192252A 1994-02-04 1995-02-02 卵巢雌激素依赖性病症的治疗 Pending CN1144486A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/191,631 1994-02-04
US08/191,631 US5681817A (en) 1994-02-04 1994-02-04 Treatment of ovarian estrogen dependent conditions

Publications (1)

Publication Number Publication Date
CN1144486A true CN1144486A (zh) 1997-03-05

Family

ID=22706258

Family Applications (1)

Application Number Title Priority Date Filing Date
CN95192252A Pending CN1144486A (zh) 1994-02-04 1995-02-02 卵巢雌激素依赖性病症的治疗

Country Status (29)

Country Link
US (1) US5681817A (OSRAM)
EP (1) EP0785792B1 (OSRAM)
JP (1) JP3130048B2 (OSRAM)
KR (1) KR970700507A (OSRAM)
CN (1) CN1144486A (OSRAM)
AP (1) AP724A (OSRAM)
AT (1) ATE179610T1 (OSRAM)
AU (1) AU689229B2 (OSRAM)
BG (1) BG62238B1 (OSRAM)
BR (1) BR9506606A (OSRAM)
CA (1) CA2182183C (OSRAM)
CZ (1) CZ291709B6 (OSRAM)
DE (1) DE69509544T2 (OSRAM)
DK (1) DK0785792T3 (OSRAM)
ES (1) ES2132645T3 (OSRAM)
FI (1) FI963036L (OSRAM)
GR (1) GR3030164T3 (OSRAM)
HU (1) HUT74622A (OSRAM)
LT (1) LT4182B (OSRAM)
LV (1) LV11782B (OSRAM)
MD (1) MD1432C2 (OSRAM)
NZ (1) NZ281441A (OSRAM)
OA (1) OA10777A (OSRAM)
PL (1) PL178273B1 (OSRAM)
RO (1) RO117420B1 (OSRAM)
RU (1) RU2110274C1 (OSRAM)
SK (1) SK96296A3 (OSRAM)
TJ (1) TJ242B (OSRAM)
WO (1) WO1995020972A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104997789A (zh) * 2006-10-24 2015-10-28 利普生物药剂公司 用于抑制子宫内膜增生的组合物和方法

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK282118B6 (sk) * 1994-07-22 2001-11-06 The Medical College Of Hampton Roads Použitie antagonistu hormónu uvoľňujúceho gonadotropíny
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
CA2306110A1 (en) 1997-10-17 1999-04-29 Mochida Pharmaceutical Co., Ltd. Therapeutic agent of uterine leiomyoma, containing dienogest as effective ingredient
US6703367B1 (en) 1999-04-27 2004-03-09 Praecis Pharmaceuticals Inc. Methods for treating hot flashes and gynaecomastia
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6417214B1 (en) * 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
AR025457A1 (es) * 1999-08-31 2002-11-27 Schering Ag Mesoprogestinas (moduladores de receptores de progesterona) para el tratamiento y la prevencion de trastornos ginecologicos benignos hormona-dependientes
US8193252B1 (en) 1999-08-31 2012-06-05 Bayer Pharma AG Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
EP1330257B1 (en) * 2000-10-30 2005-08-31 University Of Zurich Gnrh analogues for treatment of urinary incontinence
US6958142B2 (en) * 2002-08-02 2005-10-25 Balance Pharmaceuticals, Inc. Nasal spray formulation and method
US6960337B2 (en) * 2002-08-02 2005-11-01 Balance Pharmaceuticals, Inc. Methods and compositions for treating benign gynecological disorders
US7029657B2 (en) * 2002-08-02 2006-04-18 Balance Pharmaceuticals, Inc. Nasal spray steroid formulation and method
GB0302572D0 (en) 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
US8257742B2 (en) * 2005-02-17 2012-09-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Bisphosphonates for treating endometriosis
US7862552B2 (en) 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
US20060251581A1 (en) * 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
ES2643318T3 (es) * 2006-10-24 2017-11-22 Repros Therapeutics Inc. Composiciones y métodos para suprimir la proliferación endometrial
WO2008144143A1 (en) * 2007-05-14 2008-11-27 Drugtech Corporation Endometriosis treatment
JP5555631B2 (ja) * 2007-09-20 2014-07-23 ラピドット メディカル インポート アンド マーケティング リミテッド ミフェプリストンによる子宮平滑筋腫、平滑筋腫、筋腫、子宮類線維腫、子宮内膜症、または腺筋症を治療するための組成物および手段
RU2359684C1 (ru) * 2008-01-23 2009-06-27 Закрытое акционерное общество "СКАЙ ЛТД" Способ лечения эндометриоза
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
US4780461A (en) 1983-06-15 1988-10-25 Schering Aktiengesellschaft 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
DE3347126A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
ES2054784T3 (es) 1987-08-08 1994-08-16 Akzo Nv Un metodo para la fabricacion de un implante.
DE3744054A1 (de) 1987-12-21 1989-06-29 Schering Ag Verwendung von antigestagenen zur herstellung von arzneimitteln
DE3921059A1 (de) 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
WO1991014704A2 (en) 1990-03-16 1991-10-03 Applied Research Systems Ars Holding N.V. Treatment of polycystic ovarian disease
US6827050B2 (en) 2001-12-21 2004-12-07 Caterpillar Inc Fluid control valve actuating system
US7283632B2 (en) 2003-09-09 2007-10-16 The Boeing Company Unauthorized access embedded software protection system

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104997789A (zh) * 2006-10-24 2015-10-28 利普生物药剂公司 用于抑制子宫内膜增生的组合物和方法

Also Published As

Publication number Publication date
NZ281441A (en) 1999-09-29
RO117420B1 (ro) 2002-03-29
BG100766A (bg) 1997-06-30
FI963036A0 (fi) 1996-08-01
FI963036A7 (fi) 1996-08-01
DE69509544D1 (de) 1999-06-10
LT96133A (en) 1997-01-27
SK96296A3 (en) 1997-07-09
FI963036L (fi) 1996-08-01
ES2132645T3 (es) 1999-08-16
PL315792A1 (en) 1996-12-09
LV11782A (lv) 1997-06-20
DK0785792T3 (da) 1999-10-18
CA2182183C (en) 2003-09-16
EP0785792B1 (en) 1999-05-06
LT4182B (en) 1997-06-25
AP9600840A0 (en) 1996-07-31
US5681817A (en) 1997-10-28
CZ291709B6 (cs) 2003-05-14
LV11782B (en) 1997-12-20
HU9601969D0 (en) 1996-09-30
CZ210396A3 (en) 1997-05-14
KR970700507A (ko) 1997-02-12
MD1432B2 (en) 2000-03-31
AP724A (en) 1999-01-18
EP0785792A1 (en) 1997-07-30
AU1838695A (en) 1995-08-21
MD1432C2 (ro) 2000-09-30
BG62238B1 (bg) 1999-06-30
WO1995020972A1 (en) 1995-08-10
DE69509544T2 (de) 1999-09-02
EP0785792A4 (OSRAM) 1997-07-30
CA2182183A1 (en) 1995-08-10
ATE179610T1 (de) 1999-05-15
PL178273B1 (pl) 2000-03-31
JP3130048B2 (ja) 2001-01-31
TJ242B (en) 1999-11-24
AU689229B2 (en) 1998-03-26
OA10777A (en) 2002-12-23
RU2110274C1 (ru) 1998-05-10
GR3030164T3 (en) 1999-08-31
BR9506606A (pt) 1997-09-09
JPH09508418A (ja) 1997-08-26
HUT74622A (en) 1997-01-28

Similar Documents

Publication Publication Date Title
JP3130048B2 (ja) エストロゲン依存症の治療
Felberbaum et al. Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix.
Broekmans GnRH agonists and uterine leiomyomas
JP2000513326A (ja) Ｌｈｒｈアンタゴニストを用いる前立腺癌の治療方法
Coutinho et al. Regression of uterine leiomyomas after treatment with gestrinone, an antiestrogen, antiprogesterone
CN1137722C (zh) 为长期治疗方案确立基础(tonic)卵巢雌激素分泌
KR100772852B1 (ko) 자궁내막증 치료용 약제학적 조성물
BG106442A (bg) Мезопрогестини (прогестерон рецептор модулатори) за лечение и профилактика на хормонозависими доброкачествени гинекологични заболявания
EP1029868A1 (en) Hysteromyoma remedy containing dienogest as the active ingredient
US5116818A (en) Method and kit for contraception with GnRH-antagonist
Lemay Clinical appreciation of LHRH analogue formulations
LT4341B (lt) Toninės kiaušidžių estrogeno sekrecijos sureguliavimas pailgintiems terapiniams režimams
Ashok et al. The antiprogestogen mifepristone: a review
AU761274B2 (en) Pharmaceutical combination preparation that consists of LHRH-analogues and antiestrogens for treating gynecological disorders
Dima et al. NEW OPTION IN PHARMACOLOGICAL TREATMENT OF UTERINE FIBROIDS: SELECTIVE PROGESTERONE RECEPTOR MODULATORS
Monroe et al. Clinical investigations of the contraceptive and therapeutic potential of nafarelin
Vanhie et al. Medical management of endometriosis
AU5720690A (en) Use of melatonin derivatives for effecting contraception

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication